Achaogen Stock Price, News & Analysis (NASDAQ:AKAO)

$10.99 +0.17 (+1.57 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$10.99
Today's Range$10.73 - $11.04
52-Week Range$9.83 - $27.79
Volume609,075 shs
Average Volume1.14 million shs
Market Capitalization$473.23 million
P/E Ratio-3.27
Dividend YieldN/A
Beta1.27

About Achaogen (NASDAQ:AKAO)

Achaogen logoAchaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Receive AKAO News and Ratings via Email

Sign-up to receive the latest news and ratings for AKAO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:AKAO
CUSIPN/A
Phone+1-650-8003636

Debt

Debt-to-Equity Ratio0.08%
Current Ratio6.99%
Quick Ratio6.99%

Price-To-Earnings

Trailing P/E Ratio-3.27083333333333
Forward P/E Ratio-3.59
P/E GrowthN/A

Sales & Book Value

Annual Sales$41.77 million
Price / Sales11.15
Cash FlowN/A
Price / CashN/A
Book Value$3.06 per share
Price / Book3.59

Profitability

Trailing EPS($3.36)
Net Income$-71,220,000.00
Net Margins-593.61%
Return on Equity-80.44%
Return on Assets-51.17%

Miscellaneous

Employees106
Outstanding Shares42,390,000

Achaogen (NASDAQ:AKAO) Frequently Asked Questions

What is Achaogen's stock symbol?

Achaogen trades on the NASDAQ under the ticker symbol "AKAO."

How were Achaogen's earnings last quarter?

Achaogen Inc (NASDAQ:AKAO) posted its earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.72) by $0.13. The biopharmaceutical company had revenue of $0.58 million for the quarter, compared to the consensus estimate of $2.09 million. Achaogen had a negative return on equity of 80.44% and a negative net margin of 593.61%. The company's revenue was down 96.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.41) earnings per share. View Achaogen's Earnings History.

Where is Achaogen's stock going? Where will Achaogen's stock price be in 2018?

10 equities research analysts have issued 1-year price targets for Achaogen's stock. Their forecasts range from $14.00 to $31.00. On average, they expect Achaogen's share price to reach $25.44 in the next year. View Analyst Ratings for Achaogen.

What are Wall Street analysts saying about Achaogen stock?

Here are some recent quotes from research analysts about Achaogen stock:

  • 1. According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (2/14/2018)
  • 2. Mizuho analysts commented, "We believe the recent price pullback from 52-week highs presents a buying opportunity especially considering Plazomicin represents meaningful advances in the aminoglycoside class with survival benefits ." (11/9/2017)

Who are some of Achaogen's key competitors?

Who are Achaogen's key executives?

Achaogen's management team includes the folowing people:

  • Bryan E. Roberts Ph.D., Independent Chairman of the Board (Age 50)
  • Kenneth J. Hillan, President, President - R&D and Director (Age 56)
  • Blake Wise, Chief Executive Officer, Director (Age 47)
  • Tobin Schilke, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer (Age 42)
  • Lee Swem Ph.D., Senior Vice President, Chief Scientific Officer (Age 41)
  • Zeryn Sarpangal, Senior Vice President - Corporate and People Strategy (Age 35)
  • Gary Loeb, General Counsel (Age 47)
  • Janet Dorling, Chief Commercial Officer
  • Karen Bernstein Ph.D., Independent Director
  • John C. Doyle, Independent Director (Age 48)

Who owns Achaogen stock?

Achaogen's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.69%), TimesSquare Capital Management LLC (3.23%), Renaissance Technologies LLC (1.52%), Prosight Management LP (1.35%), Deutsche Bank AG (1.22%) and AXA (1.04%). Company insiders that own Achaogen stock include Blake Wise, Equity Opportunities Iv Growth, Gary Loeb, Ian Friedland, Kenneth J Hillan, Robert W Duggan, Tobin Schilke and Zeryn Sarpangal. View Institutional Ownership Trends for Achaogen.

Who sold Achaogen stock? Who is selling Achaogen stock?

Achaogen's stock was sold by a variety of institutional investors in the last quarter, including Marcus Capital LLC, Candriam Luxembourg S.C.A., Metropolitan Life Insurance Co. NY and TIAA CREF Investment Management LLC. Company insiders that have sold Achaogen company stock in the last year include Blake Wise, Gary Loeb, Kenneth J Hillan and Tobin Schilke. View Insider Buying and Selling for Achaogen.

Who bought Achaogen stock? Who is buying Achaogen stock?

Achaogen's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Prosight Management LP, Deutsche Bank AG, AXA, Quantitative Investment Management LLC, DSC Advisors L.P. and Stanley Laman Group Ltd.. Company insiders that have bought Achaogen stock in the last two years include Equity Opportunities Iv Growth and Robert W Duggan. View Insider Buying and Selling for Achaogen.

How do I buy Achaogen stock?

Shares of Achaogen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achaogen's stock price today?

One share of Achaogen stock can currently be purchased for approximately $10.99.

How big of a company is Achaogen?

Achaogen has a market capitalization of $473.23 million and generates $41.77 million in revenue each year. The biopharmaceutical company earns $-71,220,000.00 in net income (profit) each year or ($3.36) on an earnings per share basis. Achaogen employs 106 workers across the globe.

How can I contact Achaogen?

Achaogen's mailing address is 7000 Shoreline Ct Ste 371, SOUTH SAN FRANCISCO, CA 94080-7603, United States. The biopharmaceutical company can be reached via phone at +1-650-8003636 or via email at [email protected]


MarketBeat Community Rating for Achaogen (AKAO)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  245 (Vote Outperform)
Underperform Votes:  144 (Vote Underperform)
Total Votes:  389
MarketBeat's community ratings are surveys of what our community members think about Achaogen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Achaogen (NASDAQ:AKAO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.902.902.892.89
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $25.44$25.44$25.63$25.75
Price Target Upside: 131.73% upside128.20% upside82.77% upside45.40% upside

Achaogen (NASDAQ:AKAO) Consensus Price Target History

Price Target History for Achaogen (NASDAQ:AKAO)

Achaogen (NASDAQ:AKAO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/14/2018WedbushReiterated RatingPositive -> Outperform$28.00 -> $22.00HighView Rating Details
2/7/2018HC WainwrightBoost Price TargetBuy -> Buy$25.00 -> $31.00MediumView Rating Details
1/10/2018GuggenheimReiterated RatingBuy$14.00HighView Rating Details
1/3/2018MizuhoReiterated RatingBuy$28.00HighView Rating Details
1/3/2018SunTrust BanksLower Price TargetBuy$27.00HighView Rating Details
11/9/2017Stifel NicolausLower Price TargetBuy -> Buy$30.00 -> $27.00N/AView Rating Details
10/9/2017Leerink SwannReiterated RatingOutperform -> Outperform$28.00 -> $22.00N/AView Rating Details
5/15/2017CowenReiterated RatingOutperformN/AView Rating Details
3/30/2017AegisDowngradeBuy -> Hold$29.00LowView Rating Details
3/15/2017Needham & Company LLCReiterated RatingBuy$29.00MediumView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Achaogen (NASDAQ:AKAO) Earnings History and Estimates Chart

Earnings by Quarter for Achaogen (NASDAQ:AKAO)

Achaogen (NASDAQ AKAO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3($0.72)($0.85)$2.09 million$0.58 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.60)($0.78)$2.69 million$1.30 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.54)($0.93)$3.81 million$7.46 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.49)($1.04)$13.33 million$10.73 millionViewN/AView Earnings Details
11/7/2016Q3($0.61)($0.41)$8.72 million$16.05 millionViewListenView Earnings Details
8/8/2016Q2($0.67)($0.87)$5.58 million$9.14 millionViewN/AView Earnings Details
5/5/2016Q1 2016($0.60)($0.66)$5.21 million$5.85 millionViewN/AView Earnings Details
3/15/2016Q414($0.58)($0.61)$5.33 million$4.70 millionViewListenView Earnings Details
11/5/2015Q3 2015($0.46)($0.48)$5.10 million$4.48 millionViewN/AView Earnings Details
8/10/2015Q2 2015($0.20)($0.05)$8.65 million$12.04 millionViewN/AView Earnings Details
5/11/2015Q1 2015($0.25)($0.34)$5.00 million$4.88 millionViewN/AView Earnings Details
3/16/2015Q4 2014($0.33)($0.27)$4.96 million$4.26 millionViewN/AView Earnings Details
11/10/2014Q314($0.18)($0.47)$6.00 million$4.52 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.19)($0.20)$5.99 million$5.20 millionViewN/AView Earnings Details
5/12/2014Q114($0.21)($1.00)$5.39 million$6.00 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Achaogen (NASDAQ:AKAO) Earnings Estimates

2018 EPS Consensus Estimate: ($3.16)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($1.03)($0.63)($0.80)
Q2 20183($0.91)($0.69)($0.78)
Q3 20184($0.90)($0.70)($0.80)
Q4 20184($0.91)($0.61)($0.78)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Achaogen (NASDAQ:AKAO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Achaogen (NASDAQ AKAO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.36%
Institutional Ownership Percentage: 90.49%
Insider Trades by Quarter for Achaogen (NASDAQ:AKAO)
Institutional Ownership by Quarter for Achaogen (NASDAQ:AKAO)

Achaogen (NASDAQ AKAO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/21/2018Blake WiseCEOSell1,640$10.67$17,498.80View SEC Filing  
2/21/2018Kenneth J. HillanInsiderSell4,606$10.67$49,146.02View SEC Filing  
2/21/2018Tobin SchilkeCFOSell1,108$10.67$11,822.36View SEC Filing  
2/14/2018Robert W DugganMajor ShareholderBuy10,000$10.96$109,600.005,668,310View SEC Filing  
1/5/2018Robert W DugganMajor ShareholderBuy50,000$11.51$575,500.005,617,752View SEC Filing  
1/3/2018Robert W DugganMajor ShareholderBuy15,000$10.89$163,350.005,617,752View SEC Filing  
12/18/2017Robert W DugganMajor ShareholderBuy95,012$11.13$1,057,483.565,602,752View SEC Filing  
9/26/2017Blake WiseCOOSell3,576$15.99$57,180.24View SEC Filing  
9/26/2017Gary LoebGeneral CounselSell1,146$15.99$18,324.54View SEC Filing  
6/12/2017Tobin SchilkeCFOSell2,066$21.53$44,480.98View SEC Filing  
1/26/2017Gary LoebGeneral CounselSell521$16.78$8,742.38View SEC Filing  
1/26/2017Ian FriedlandInsiderSell695$16.78$11,662.10View SEC Filing  
1/26/2017Kenneth J. HillanCEOSell1,431$16.78$24,012.18View SEC Filing  
1/26/2017Tobin SchilkeCFOSell955$16.78$16,024.90View SEC Filing  
1/26/2017Zeryn SarpangalVPSell781$16.78$13,105.18View SEC Filing  
12/19/2016Equity Opportunities Iv GrowthMajor ShareholderBuy500,000$13.50$6,750,000.00View SEC Filing  
9/27/2016Blake WiseCOOSell3,632$4.30$15,617.60View SEC Filing  
9/27/2016Zeryn SarpangalVPSell1,069$4.30$4,596.70View SEC Filing  
3/17/2016Ian FriedlandInsiderSell1,772$3.22$5,705.8432,728View SEC Filing  
3/17/2016Kenneth J HillanCEOSell3,572$3.22$11,501.8461,628View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Achaogen (NASDAQ AKAO) News Headlines

Source:
DateHeadline
 Analysts Expect Achaogen Inc (AKAO) to Post -$0.79 Earnings Per Share Analysts Expect Achaogen Inc (AKAO) to Post -$0.79 Earnings Per Share
www.americanbankingnews.com - February 24 at 5:12 AM
Achaogen Inc (AKAO) CFO Tobin Schilke Sells 1,108 SharesAchaogen Inc (AKAO) CFO Tobin Schilke Sells 1,108 Shares
www.americanbankingnews.com - February 23 at 9:42 PM
Achaogen Inc (AKAO) CEO Sells $17,498.80 in StockAchaogen Inc (AKAO) CEO Sells $17,498.80 in Stock
www.americanbankingnews.com - February 23 at 9:42 PM
Kenneth J. Hillan Sells 4,606 Shares of Achaogen Inc (AKAO) StockKenneth J. Hillan Sells 4,606 Shares of Achaogen Inc (AKAO) Stock
www.americanbankingnews.com - February 23 at 9:40 PM
Traders Purchase Large Volume of Achaogen Put Options (AKAO)Traders Purchase Large Volume of Achaogen Put Options (AKAO)
www.americanbankingnews.com - February 23 at 8:26 AM
Q4 2017 EPS Estimates for Achaogen Inc Increased by Wedbush (AKAO)Q4 2017 EPS Estimates for Achaogen Inc Increased by Wedbush (AKAO)
www.americanbankingnews.com - February 16 at 6:04 AM
Achaogen Inc (AKAO) Major Shareholder Robert W. Duggan Buys 10,000 SharesAchaogen Inc (AKAO) Major Shareholder Robert W. Duggan Buys 10,000 Shares
www.americanbankingnews.com - February 15 at 10:04 PM
Achaogen (AKAO) PT Set at $22.00 by WedbushAchaogen (AKAO) PT Set at $22.00 by Wedbush
www.americanbankingnews.com - February 14 at 10:40 PM
Achaogen (AKAO) Cut to "Sell" at Zacks Investment ResearchAchaogen (AKAO) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - February 14 at 4:20 PM
Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2017 Financial Results on February 27, 2018Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2017 Financial Results on February 27, 2018
finance.yahoo.com - February 13 at 8:37 AM
$1.78 Million in Sales Expected for Achaogen Inc (AKAO) This Quarter$1.78 Million in Sales Expected for Achaogen Inc (AKAO) This Quarter
www.americanbankingnews.com - February 9 at 4:34 AM
Achaogen to Present at the Leerink Partners 7th Annual Global Healthcare Conference - GlobeNewswire (press release)Achaogen to Present at the Leerink Partners 7th Annual Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - February 8 at 8:04 AM
Achaogen Inc (AKAO) Expected to Post Earnings of -$0.79 Per ShareAchaogen Inc (AKAO) Expected to Post Earnings of -$0.79 Per Share
www.americanbankingnews.com - February 7 at 5:10 AM
Achaogen Inc (AKAO) Receives Consensus Recommendation of "Buy" from AnalystsAchaogen Inc (AKAO) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 6 at 10:40 AM
Achaogen (AKAO) Rating Lowered to Sell at Zacks Investment ResearchAchaogen (AKAO) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - February 5 at 4:54 PM
Technical Perspectives on Biotech Stocks -- ACADIA Pharma ... - PR Newswire (press release)Technical Perspectives on Biotech Stocks -- ACADIA Pharma ... - PR Newswire (press release)
www.prnewswire.com - February 5 at 3:35 PM
Technical Perspectives on Biotech Stocks -- ACADIA Pharma, Achaogen, Achillion Pharma, and Acorda TherapeuticsTechnical Perspectives on Biotech Stocks -- ACADIA Pharma, Achaogen, Achillion Pharma, and Acorda Therapeutics
www.bizjournals.com - February 5 at 8:33 AM
Achaogen, Plazomicin NDAs Upcoming PDUFA Review and the Change to VAI StatusAchaogen, Plazomicin NDA's Upcoming PDUFA Review and the Change to VAI Status
finance.yahoo.com - February 1 at 8:37 AM
Here’s What’s Moving Bellicum Pharmaceuticals And AchaogenHere’s What’s Moving Bellicum Pharmaceuticals And Achaogen
finance.yahoo.com - January 31 at 3:36 PM
Zacks Investment Research Lowers Achaogen (AKAO) to SellZacks Investment Research Lowers Achaogen (AKAO) to Sell
www.americanbankingnews.com - January 30 at 4:52 PM
Heres Why Achaogen Inc Rose as Much as 16.9% TodayHere's Why Achaogen Inc Rose as Much as 16.9% Today
www.fool.com - January 30 at 3:37 PM
BRIEF-Achaogen Announces Upgraded Status For Plazomicin Fill ManufacturerBRIEF-Achaogen Announces Upgraded Status For Plazomicin Fill Manufacturer
www.reuters.com - January 30 at 3:37 PM
Here's Why Achaogen Inc Rose as Much as 16.9% TodayHere's Why Achaogen Inc Rose as Much as 16.9% Today
finance.yahoo.com - January 30 at 3:37 PM
Achaogen Inc (AKAO) Expected to Announce Earnings of -$0.79 Per ShareAchaogen Inc (AKAO) Expected to Announce Earnings of -$0.79 Per Share
www.americanbankingnews.com - January 21 at 9:42 AM
Achaogen Inc (AKAO) Given Consensus Rating of "Buy" by BrokeragesAchaogen Inc (AKAO) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 12 at 8:02 AM
Zacks: Brokerages Anticipate Achaogen Inc (AKAO) Will Announce Quarterly Sales of $1.78 MillionZacks: Brokerages Anticipate Achaogen Inc (AKAO) Will Announce Quarterly Sales of $1.78 Million
www.americanbankingnews.com - January 6 at 4:32 AM
Brokers Issue Forecasts for Achaogen Incs FY2022 Earnings (AKAO)Brokers Issue Forecasts for Achaogen Inc's FY2022 Earnings (AKAO)
www.americanbankingnews.com - January 5 at 8:40 PM
Robert W. Duggan Acquires 50,000 Shares of Achaogen Inc (AKAO) StockRobert W. Duggan Acquires 50,000 Shares of Achaogen Inc (AKAO) Stock
www.americanbankingnews.com - January 5 at 6:32 PM
Robert W. Duggan Buys 15,000 Shares of Achaogen Inc (AKAO) StockRobert W. Duggan Buys 15,000 Shares of Achaogen Inc (AKAO) Stock
www.americanbankingnews.com - January 5 at 6:32 PM
FY2018 EPS Estimates for Achaogen Inc Raised by SunTrust Banks (AKAO)FY2018 EPS Estimates for Achaogen Inc Raised by SunTrust Banks (AKAO)
www.americanbankingnews.com - January 4 at 5:10 PM
BRIEF-Achaogen Announces FDA Acceptance Of New Drug Application With Priority Review For PlazomicinBRIEF-Achaogen Announces FDA Acceptance Of New Drug Application With Priority Review For Plazomicin
www.reuters.com - January 3 at 3:34 PM
Achaogen's NDA for Plazomicin Gets Priority Review From FDAAchaogen's NDA for Plazomicin Gets Priority Review From FDA
finance.yahoo.com - January 3 at 10:53 AM
Achaogen (AKAO) Plazomicin NDA Accepted with Priority Review; June 25th PDUFA Date - StreetInsider.comAchaogen (AKAO) Plazomicin NDA Accepted with Priority Review; June 25th PDUFA Date - StreetInsider.com
www.streetinsider.com - January 2 at 8:52 PM
BRIEF-Achaogen Announces Positive Top-Line Results From First Clinical Trial Of Orally-Administered Antibacterial Candidate C-ScapeBRIEF-Achaogen Announces Positive Top-Line Results From First Clinical Trial Of Orally-Administered Antibacterial Candidate C-Scape
www.reuters.com - January 2 at 11:10 AM
Achaogen stock surges 3% after FDA plans to review its UTI therapyAchaogen stock surges 3% after FDA plans to review its UTI therapy
finance.yahoo.com - January 2 at 11:10 AM
ETFs with exposure to Achaogen, Inc. : December 26, 2017ETFs with exposure to Achaogen, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 12:45 PM
Achaogen, Inc. (AKAO) Major Shareholder Robert W. Duggan Purchases 95,012 SharesAchaogen, Inc. (AKAO) Major Shareholder Robert W. Duggan Purchases 95,012 Shares
www.americanbankingnews.com - December 20 at 8:26 PM
Zacks: Analysts Anticipate Achaogen, Inc. (AKAO) Will Announce Quarterly Sales of $1.78 MillionZacks: Analysts Anticipate Achaogen, Inc. (AKAO) Will Announce Quarterly Sales of $1.78 Million
www.americanbankingnews.com - December 20 at 3:50 AM
Achaogen, Inc. (AKAO) Short Interest UpdateAchaogen, Inc. (AKAO) Short Interest Update
www.americanbankingnews.com - December 18 at 4:36 PM
Achaogen, Inc. (AKAO) Given Average Recommendation of "Buy" by AnalystsAchaogen, Inc. (AKAO) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 18 at 8:44 AM
Financial Comparison: Achaogen (AKAO) and Xencor (XNCR)Financial Comparison: Achaogen (AKAO) and Xencor (XNCR)
www.americanbankingnews.com - December 12 at 11:16 PM
Achaogen Appoints Blake Wise Chief Executive Officer - GlobeNewswire (press release)Achaogen Appoints Blake Wise Chief Executive Officer - GlobeNewswire (press release)
globenewswire.com - December 12 at 11:56 AM
Achaogen (AKAO) Lifted to "Hold" at Zacks Investment ResearchAchaogen (AKAO) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - December 11 at 7:16 PM
Achaogen, Inc. (AKAO) Expected to Post Quarterly Sales of $1.78 MillionAchaogen, Inc. (AKAO) Expected to Post Quarterly Sales of $1.78 Million
www.americanbankingnews.com - December 2 at 6:00 AM
Achaogen, Inc. (AKAO) Expected to Post Earnings of -$0.79 Per ShareAchaogen, Inc. (AKAO) Expected to Post Earnings of -$0.79 Per Share
www.americanbankingnews.com - November 30 at 9:32 PM
Achaogen (AKAO) Earns Buy Rating from MizuhoAchaogen (AKAO) Earns Buy Rating from Mizuho
www.americanbankingnews.com - November 30 at 4:42 PM
Achaogen to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference - GlobeNewswire (press release)Achaogen to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - November 30 at 11:49 AM
Is the Options Market Predicting a Spike in Achaogen (AKAO) Stock? - NasdaqIs the Options Market Predicting a Spike in Achaogen (AKAO) Stock? - Nasdaq
www.nasdaq.com - November 27 at 3:21 PM
Achaogen, Inc. (AKAO) Receives Consensus Rating of "Buy" from BrokeragesAchaogen, Inc. (AKAO) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 23 at 10:10 AM
Investors Purchase Large Volume of Achaogen Put Options (AKAO)Investors Purchase Large Volume of Achaogen Put Options (AKAO)
www.americanbankingnews.com - November 23 at 1:34 AM

SEC Filings

Achaogen (NASDAQ:AKAO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Achaogen (NASDAQ:AKAO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Achaogen (NASDAQ AKAO) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.